7. Desescalada de tratamiento en pacientes con cáncer de mama precoz de bajo riesgo

Flora López López

Flora López López Oncología Médica. Hospital Universitario del Sureste. Arganda del Rey. Madrid.

Palabras clave: Cáncer mama precoz, Radioterapia

Abstract

La radioterapia adyuvante tras cirugía conservadora de cáncer de mama precoz es un estándar terapéutico. Sin embargo, pacientes de bajo riesgo de recaída por edad, estadio y fenotipo tumoral que realizan hormonoterapia adyuvante, parecen obtener un beneficio modesto de la irradiación mamaria pudiendo plantear su omisión en este subgrupo.

Adjuvant radiotherapy after breast-conserving surgery for early breast cancer is a standard of care. However, patients at low risk of relapse due to age, stage and tumour phenotype who undergo adjuvant hormone therapy, seem to obtain a modest benefit from breast irradiation and its omission may be considered in this subgroup.

Citas

Vol 24 Nº1; págs. 52-62. 2017. Meattini, I., Guenzi, M., Fozza, A. et al. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer. Doi: 10.1007/s12282-016-0694-3.

Vol 31 Nº19; págs. 2382-7. 2013. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. Doi: 10.1200/JCO.2012.45.2615.

Vol 395 Nº 10237; págs. 1613-1626. 2020. Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. Doi: 10.1016/S0140-6736(20)30932-6.

Vol 33 Nº 1; págs. 19-25. 2019. Wapnir IL, Khan A. Current Strategies for the Management of Locoregional Breast Cancer Recurrence. Oncology (Williston Park). PMID: 30731014.

Vol 126 Nº 2; págs. 529-37. 2011. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. Doi: 10.1007/s10549-010-1132-4.